Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Significant Growth in Short Interest

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 447,500 shares, a growth of 107.2% from the August 31st total of 216,000 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 4,475.0 days. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 4,475.0 days.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $30.05 on Friday. The company has a market capitalization of $10.70 billion, a price-to-earnings ratio of 25.25 and a beta of 0.49. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.00 and a quick ratio of 0.66. The business has a 50-day moving average of $29.77 and a two-hundred day moving average of $29.48. Swedish Orphan Biovitrum has a 1 year low of $25.80 and a 1 year high of $32.01.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.06. The company had revenue of $649.61 million during the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a return on equity of 11.67% and a net margin of 16.05%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.